Skip to search formSkip to main contentSkip to account menu

Lenzilumab

Known as: Immunoglobulin G1-kappa, Anti-(Homo sapiens CSF2 (Colony Stimulating Factor 2 (Granulocyte-Macrophage), Granulocyte Macrophage Colony Stimulating Factor, GM-CSF)), Homo sapiens Monoclonal Antibody 
A recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating… 
National Institutes of Health

Related topics

Related topics

6 relations
Antibody-Dependent Cellular CytotoxicityB-LymphocytesCytotoxic T-LymphocytesNCIt Antineoplastic Agent Terminology

Narrower (1)

KB 003

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
COVID vaccine results pour in
the drug as a frontrunner among the anti-GM-CSF mAbs under development. Mavrilimumab eliminated deaths in the treated group, with… 
Review
2019
Review
2019
A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti-Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML)
BACKGROUND: CMML is a myelodysplastic/myeloproliferative neoplasm with a median survival of 32 months and no therapies that… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)